Lifecare (LIFE)

[Kallep]

Kanskje det blir meir enn berre fagre løfter fra DD etter kvart:

Digid - Qindle - Innovation & Design

Mulig det kjem ei godkjenning fra BfArM snart…

[Evilfreud]

Er vel ingenting som tyder på at en godkjenning er nært forestående.

[Rolsu]

Det skal vist være et animert bilde.

“skremmende at ting er så klart at de må kjøre CGI bilder og ikke ekte produkter.”
Fra xi

[TekBot]

Lifecare (Life) recieves regulatory approval for first-in-human Clinical Pilot Evaluation

Bergen, February 15th, 2021 - Lifecare AS (LIFE)

Lifecare has received regulatory approval for the first-in-human Sencell Clinical Study Protocol from the German Federal Institute for Drugs and Medical Devices (BfArM). With this final remaining approval, Lifecare has reached its goal to have clinical pilot trial permission as planned in Q1 2021.
…

Vis børsmeldingen

Lifecare CEO Joacim Holter says, “With this regulatory approval, Lifecare has achieved a major milestone in the development of the Sencell implantable continuous glucose sensor for reliable, and long-lasting glucose measurement for routine medical care.”

“The upcoming clinical pilot study will generate first human data for measuring interstitial glucose during standardized meal tests in subjects with and without diabetes,” says Lifecare CSO Prof. Andreas Pfützner.

With this first performance evaluation, Lifecare aims to increase the base for interpreting read-out signals in human subjects. This data will be used to develop and optimize algorithms in future wireless and wired versions of the Sencell osmotic pressure sensors.

Lifecare plans for additional pre-clinical and clinical trials in 2H 2021, preparing to later initiate the CE mark approval process for the Sencell osmotic pressure sensor technology.

Based on nano-sensor technology, Lifecare has over the last year succeeded in miniaturizing the Sencell sensor to a point smaller than the initially targeted size. This has made it possible to incorporate the Sencell core sensor into a needle sensor version of the device, which will be employed in theses first studies. This also opens new collaboration opportunities with existing needle sensor companies.

The Sencell sensor is an osmotic pressure based wireless sensor to measure tissue glucose with a usage time of more than 6 months. Lifecare envisions that the Sencell technology also can make a difference as the core component in a needle glucose sensor device to increase the usage time for wired solutions beyond 10-14 days.

Sencell is the dedicated sensing element in the EU-funded project FORGETDIABETES where Lifecare, in partnership with European research institutions, aims to develop a miniaturized closed-loop artificial pancreas device. It is planned to be implanted in the abdominal cavity to deliver the correct amount of insulin based on continuous glucose readings provided by the Sencell technology.

While glucose measurements represent the key focus developing the Sencell technology, additional areas of use are considered on an ongoing basis.

For more information, please contact:

Joacim Holter, CEO
Phone: +47 40 05 90 40
Email: joacim.holter@lifecare.no

Lifecare (LIFE) is a Bergen-based technology company developing a miniaturized implantable long-term sensor for glucose measurement for people with diabetes mellitus. Its patented technology is also used as a central component in a current rapid SARS-CoV-2 antigen test development and in other future diagnostic tests.

Kilde

[Investor6]

Gratulerer til Lifecare og til de som er inne i selskapet! Aksjen steg 36% i dag!

Det neste som forventes med det første er at DD får godkjent hurtigtesten sin.

Life kan fort bli den norske aksjevinneren i de kommende 3 årene.

[Evilfreud]

DD må vel få lov til å teste hurtigtesten sin først?

Får håpe mange fikk reddet inn mye rødt idag slik at man kan komme seg ut med pengene i behold.

[Investor6]

Enkelte synes å ha en religiøs motstand mot Lifecare på lik linje som CNN og norsk medias konsekvente negative vinkling av forhenværende president Trump !

Personlig har jeg tjent 83% avkastning de siste månedene ved ikke å følge Evilfreud sine strenge anbefalinger om å skygge unna Life!

Når godkjenning av hurtigtesten kommer nå med det første så tror jeg det blir mer enn dagens 36% oppgang i aksjekursen.

[Evilfreud]

Life har en historikk, som de fortsetter å bekrefte. Da handler det vel mest om at enkelte desperat prøver å lure inn andre slik at de selv kan komme seg ut i plus.

Dette ser vi igjen og igjen og de som ligger mest i rødt er ofte de som stadig endrer narrativ for å få den minste ting til å fremstå positivt.

Når er det jo bra de får lov å teste sencell. Men noe annet ville vært rart.

[Snippa]

Ja det er rart med det, at sånne proffe som deg alltid treffer bunn og gjerne har solgt på topp. Her tror jeg du farer med løgn

[Hypergris]

@Evilfreud

enkelte desperat prøver å lure inn andre slik at de selv kan komme seg ut i plus.

Fifan:D

[Investor6]

Hvem sier at jeg har solgt? Jeg sitter langsiktig og venter på videre kraftig kursoppgang for Life i de kommende årene!

[Fartin]

The world’s first Point-of-Care (PoC) SARS-CoV-2 antigen test, which is based on digid’s proprietary biosensor technology Cantisense ™, was recently submitted to the international authorities for marketing approval.

Werkstudent - Softwareentwicklung / Python (m/w/d) - Job bei Campusjäger GmbH...

Hvor mange selskaper har søknad inne til vurdering på legemiddel device på.oslo børs?

Den teksten der fra stillingsannonser til.digid er for meg ett sterkt kjøpssignal

[TekBot]

Lifecare AS (LIFE) Digid Cantisense Update

March 19th, 2021, Bergen - Lifecare’s partner, Digital Diagnostics AG (Digid), has developed a novel 5-minute antigen rapid virus detection test. The Cantisense test method is based on proteins binding onto the virus antigen, which leads to electronically measurable changes. The method is highly sophisticated and advanced compared to already existing virus detection test methods:

• The monoclonal antibody technology used enables highly specific and high affinity binding, enabling high sensitivity and reliability of the test.
  …

Vis børsmeldingen

• Further development of the technology provides a platform-character for detection of various bio- and disease markers with short lead-time for upcoming regulatory approvals and market entry.

Cantisense development status
In Q4 2020 Digid intensified its efforts and has conducted further important testing of the Cantisense SARS-CoV-2-Test.

The remaining product development depends on frequent and repeated accesses to S3 high security laboratories to resemble data generation under real world conditions by measuring on the active SARS-CoV-2 virus. There are few S3 laboratories in Europe with access to living cultivated Covid-19 viruses. These S3 labs are currently overwhelmed with requests from development partners. With reduced access to S3 labs, Digid’s testing and analysis is currently delayed. This postpones the final process to prepare for ISO 13485 certification, a quality system enabling the company to market certified (CE mark) medical devices in the European Union and associated countries, and commercialization.

“The overall development at Digid is good and we are happy with the test results so far. The S3 labs with cultivated Covid-19 viruses are naturally overwhelmed with requests, which is delaying Digid’s testing and analysis. We are confident that Digid’s new type of virus detection will be brought to the market, although the timeline for bringing Cantisense SARS-CoV-2-Test to market has turned out longer than previously indicated,” says Joacim Holter, CEO of Lifecare, Digid’s partner.

While waiting on access to the labs, Digid is further optimizing the technology to ensure a solid platform for various detection tests with a short lead-time for upcoming regulatory approvals and market entry. In the process of bringing the new test from the lab to the market, Digid has solved major logistical challenges related to production. The technology is expected to be applied for other diagnostic tests as well and this will be further explored.

For more information, please contact:
Joacim Holter, CEO
Phone: +47 40 05 90 40
Email: joacim.holter@lifecare.no

Lifecare (LIFE-ME) is a Bergen-based technology company developing a miniature sensor for correct and continuous monitoring of diabetics’ blood sugar. Its patented technology is also used as a central component in a rapid test for Covid-19 and as a measurement unit for reading out different biomarkers.

Kilde

[Kronn]

Yeah, kjøpte Life før idag

[rayman]

Forsinket… Igjen…selskapet sitt dette

[boella]

Hei Investor6
Jeg har også sittet langsiktig siden jeg kjøpte på 6,9. Det har blitt veldig langsiktig, siden jeg ikke vil selge med tap. Men jeg selger med en gang denne passerer 6,9.
I mer enn et halvt år har vi fått vite at DD skulle gjøre kursen himmelhøy og alle skulle bli rike. Og dette skulle skje om noen dager, eller i hvert fall neste uke. Sjekk ut Life-trådene på FA forum. Det virker vel nærmest religiøst, troen på denne aksjen, frelsen kommer snart, uke etter uke. Men i dag kom det en melding som umiddelbart løftet aksjen, inntil folk fikk finlest hva som egentlig stod der - og da ble det umiddelbart nedtur. Tror at det hadde vært klokest å ikke sende denne børsmeldingen som det strengt tatt ikke hadde vært påkrevet som et børskrav… eller?

[Investor6]

Sitter langsiktig i Life pga. Sencell som jeg tror vil bli banebrytende for både pasienter og selskapet.
Lifes eksponering i DD blir, i tilfelle de lykkes, som en bonus å regne.
God helg!

[boella]

Hei Investor6
Respekterer din langsiktige tenkning på Lifecares egne produkter, det er vel kan hende fornuftig. Jeg klager vel imidlertid egentlig litt på DD euforien, som faktisk lokket meg inn i aksjen. Og der føler jeg meg lurt, noe som er min egen tabbe,der jeg bare kan skylde meg selv.
Mvh
boella

[TekBot]

The European Patent Office intends to issue new Lifecare patent

25 March 2021, Bergen – Today, Lifecare announces that The European Patent Office has issued its intent to grant Lifecare a new patent, expanding Lifecare’s patent protection in time and scope. Lifecare has reviewed the examining division’s comments to the patent application and concludes that the suggested cosmetic changes are acceptable. On this base, Lifecare expects the European Patent Office to grant the patent within the next few months.

The new patent will ensure protection until 2038. It will be a fundamental addition to Lifecare’s IP and an important next step from Lifecare’s research and development to commercialization.
…

Vis børsmeldingen

The patent is for an updated sensor measuring system comprised of the well-known and already proprietary osmotic pressure based Sencell core technology for glucose, and an additional reference sensor to measure environmentally induced general pressure changes. The patent is for Lifecare’s application of “interstitial fluid osmotic pressure measuring device system and method.”

“This European patent will strengthen our position for correct and continuous monitoring of blood sugar, in people with diabetes, through the development of a miniature sensor. The patent covers Lifecare’s Sencell technology in the sensor, which is the size of a grain of rice, that will be used in the recently approved human pilot studies,” says Joacim Holter, CEO Lifecare. “Existing continuous glucose measurement technologies are inconvenient, complicated, costly, and have limited lifetime. The sensor design described in our new patent intends to improve signal amplitude, increase the accuracy of subcutaneous glucose assessment, and to improve sensor longevity and robustness against environmental changes.”

Patent broadens the scope and application of the Sencell technology
The patent opens up the opportunities to expand the use of the Sencell technology. It will increase the scope of protection to include measurement of many parameters in the interstitial fluid, including but not limited to lactate, fructose, and calcium, in addition to glucose.

“This new patent substantially strengthens the protection of Lifecare’s core Sencell technology,” says Prof. Andreas Pfützner, Lifecare’s Chief Scientific Officer and one of the inventors of the new patent. “The patent covers an essential part of the sensor design, which will be important when we start to use Sencell for additional analysis, beyond glucose, in the future.”

About Lifecare
Lifecare (LIFE-ME) is a Bergen-based technology company developing a miniature sensor for correct and continuous monitoring of blood sugar in people with diabetes. Its patented technology is also used as a central component in a rapid test for Covid-19 and as a measurement unit for reading out different biomarkers.

For more information, please contact:
Joacim Holter, CEO
Phone: +47 40 05 90 40
Email: joacim.holter@lifecare.no

Kilde

[boella]

Hei Investor6
Jeg har tenkt, lenge og vel og har fått et mer positivt forhold til aksjen, så lenge jeg kan koble vekk tanken på DD, som må være utrolig talentløst håndtert dersom produktet er så revolusjonerende som annonsert en rekke ganger fra ledelsen i Life. Akkurat som forrige børsmelding var kontraproduktiv og unødvendig.
Takk skal du ha.
Mvh
boella